EVH vs. RCM, PINC, FC, IT, MNDY, GWRE, ONTO, NICE, EPAM, and CYBR
Should you be buying Evolent Health stock or one of its competitors? The main competitors of Evolent Health include R1 RCM (RCM), Premier (PINC), Franklin Covey (FC), Gartner (IT), monday.com (MNDY), Guidewire Software (GWRE), Onto Innovation (ONTO), NICE (NICE), EPAM Systems (EPAM), and CyberArk Software (CYBR).
R1 RCM (NASDAQ:RCM) and Evolent Health (NYSE:EVH) are both mid-cap business services companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, community ranking, risk, valuation, analyst recommendations, media sentiment and institutional ownership.
R1 RCM has a net margin of -1.39% compared to R1 RCM's net margin of -5.07%. R1 RCM's return on equity of 6.90% beat Evolent Health's return on equity.
Evolent Health received 262 more outperform votes than R1 RCM when rated by MarketBeat users. Likewise, 73.88% of users gave Evolent Health an outperform vote while only 57.94% of users gave R1 RCM an outperform vote.
R1 RCM has higher revenue and earnings than Evolent Health. R1 RCM is trading at a lower price-to-earnings ratio than Evolent Health, indicating that it is currently the more affordable of the two stocks.
61.1% of R1 RCM shares are held by institutional investors. 36.8% of R1 RCM shares are held by insiders. Comparatively, 1.6% of Evolent Health shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
In the previous week, Evolent Health had 1 more articles in the media than R1 RCM. MarketBeat recorded 4 mentions for Evolent Health and 3 mentions for R1 RCM. Evolent Health's average media sentiment score of 1.32 beat R1 RCM's score of 1.22 indicating that R1 RCM is being referred to more favorably in the media.
R1 RCM has a beta of 0.86, meaning that its share price is 14% less volatile than the S&P 500. Comparatively, Evolent Health has a beta of 1.44, meaning that its share price is 44% more volatile than the S&P 500.
R1 RCM presently has a consensus price target of $16.31, indicating a potential upside of 29.63%. Evolent Health has a consensus price target of $42.00, indicating a potential upside of 75.59%. Given R1 RCM's stronger consensus rating and higher possible upside, analysts clearly believe Evolent Health is more favorable than R1 RCM.
Summary
Evolent Health beats R1 RCM on 10 of the 18 factors compared between the two stocks.
Get Evolent Health News Delivered to You Automatically
Sign up to receive the latest news and ratings for EVH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding EVH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Evolent Health Competitors List
Related Companies and Tools
